Register
Login:
Share:
Email Facebook Twitter

SOU CEO responds to investor questions on its projects in Morocco and Italy. Watch here

Share ViewsEp. 20
SOU CEO responds to investor questions on its projects in Morocco and Italy


Scancell Holdings Share Price (SCLP)



Share Price Information for Scancell Holdings (SCLP)


Share Price: 14.75Bid: 14.50Ask: 15.00Change: 0.00 (0.00%)No Movement on Scancell Hldgs
Spread: 0.50Spread as %: 3.45%Open: 14.75High: 14.75Low: 14.75Yesterday’s Close: 14.75

Scancell Holdings Plc Ord 0.1P

Scancell Holdings is listed in the FTSE AIM All-Share
Scancell Holdings is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
14.75

Share Price SpacerBid
14.50

Share Price SpacerAsk
15.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
7,002

Share Price SpacerOpen
14.75

Share Price SpacerHigh
14.75

Share Price SpacerLow
14.75

Share Price SpacerClose
14.75

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 261.56m £38.58m 10,000

52 Week High 24.50 52 Week High Date 29-DEC-2015
52 Week Low 13.00 52 Week Low Date 17-JUN-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
2 5,742 1,260 -12.939 -1.14 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

09-Dec-16
14:09:34
14.88
1,260
Buy* 
14.50
15.00
187.49
Trade Type:
Ordinary

09-Dec-16
08:02:07
14.55
5,742
Sell* 
14.50
15.00
835.46
Trade Type:
Ordinary

08-Dec-16
15:16:09
14.55
20,000
Sell* 
14.50
15.00
2,910
Trade Type:
Ordinary




View more Scancell Holdings trades >>

Directors Deals for Scancell Holdings (SCLP)
Trade DateActionNotifierPriceCurrencyAmountHolding
10-Dec-13Notification of Holding
Trade Notifier Information for Scancell Holdings
Lindy Durrant held the position of CEO at Scancell Holdings at the time of this trade.
 Lindy Durrant
000
10-Dec-13Notification of Holding
Trade Notifier Information for Scancell Holdings
Richard Goodfellow held the position of Joint CEO at Scancell Holdings at the time of this trade.
 Richard Goodfellow
000
21-Oct-13Sell
Trade Notifier Information for Scancell Holdings
Lindy Durrant held the position of CEO at Scancell Holdings at the time of this trade.
 Lindy Durrant
30GBX100,0000
View more Scancell Holdings directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Today 17:57CHELSEA7RE: Chelsea14.75Strong Buy
Hi Wild, I am seeing my oncologist Monday who is also conducting a fairly large Car-T trial at UCLH.

I have a few questions for him re Car-T and will post next week anything key.

Have a good weekend all.
Today 17:05WildforceChelsea14.75Strong Buy
More fine tuning? .. Wonder if that will put the cost even further out of reach for , well, pretty much everyone !

Just read this ... 'The best is yet to come' ... I think so too..

http://www.curetoday.com/publications/cure/2016/melanoma-2016-2/working-at-the-speed-of-light-in-melanoma-advancements?p=1

Take care all ..
Today 17:01CHELSEA7Car-T Safety Issues14.75Strong Buy
Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects?
Monday, December 5, 2016

At the ASH meeting in San Diego, Kite Pharma and Novartis presented impressive data on their chimeric antigen receptor T-cell (CAR-T) therapies to treat blood cancers, and both appear to be on track to file for FDA approval soon. But concerns about toxic side effects continue to dog this emerging form of immunotherapy. Now a set of researchers at the Fred Hutchinson Cancer Research Center in… Read More
Today 17:00CHELSEA7CarT- latest14.75Strong Buy
Rivals Kite and Novartis post new CAR-T data as both plot FDA approval
Monday, December 5, 2016

Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early next year with the FDA, but rival Kite Pharma is hot on its heels as it starts a rolling submission with the regulator.
Today 10:52CHELSEA7RE: Bibio14.75Strong Buy
This one stood out for me Boom...................

10. Work backward from your target company profile and your target product profile. Is your vision to create a single-product company or one with a rich pipeline of drugs? Do you want to hold on for the long run or sell early? Your answer to what kind of company you want to build has dozens of strategic implications. When you finally have a product in the clinic, ask what target product profile will actually compel a clinician to prescribe?… Read More
Today 09:18CHELSEA7RE: First Word14.75Strong Buy
Morning Ivy, and lets hope we figure large in this batch.

Hope all well and "watching".

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Scancell Holdings (SCLP) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.